कृपया अन्य खोज का प्रयास करें
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Vlad Ratziu | - | - | Member of Scientific Advisory Board |
Arun J. Sanyal | - | - | Member of Scientific Advisory Board |
Shmuel Nir | 59 | 2007 | Independent Director |
Amir Poshinski | 60 | 2020 | Independent Director |
David Sidransky | 61 | 2014 | Lead Independent Director |
Allen Baharaff | 56 | 2000 | Co-Founder, President, CEO & Chairman |
José María Mato de la Paz | - | - | Member of Scientific Advisory Board |
Shomron Ben-Horin | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Carol L. Brosgart | 72 | 2017 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है